Philogen SpA ( (IT:PHIL) ) has issued an announcement.
Philogen S.p.A. has announced an update on its share buyback program, revealing the purchase of 2,156 shares between February 17 and February 21, 2025, at an average price of Euro 18.2817 per share, totaling Euro 39,415.44. This initiative is part of a broader strategy to manage the company’s capital structure and potentially enhance shareholder value, with Philogen having acquired a total of 26,025 shares since the program’s inception.
More about Philogen SpA
Philogen is an Italian-Swiss biotechnology company focused on the research and development of pharmaceutical products targeting high-mortality diseases, primarily through the creation of targeted anti-cancer drugs using advanced ligand technologies. The company specializes in tumor targeting strategies to deliver potent therapeutic agents selectively to tumors, aiming to develop innovative treatments for diseases lacking satisfactory therapies.
YTD Price Performance: -7.63%
Average Trading Volume: 297
Technical Sentiment Consensus Rating: Buy
Current Market Cap: €539.5M
For a thorough assessment of PHIL stock, go to TipRanks’ Stock Analysis page.